-
China Nrdl Drug List, Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China’s GAVRETO® (pralsetinib) successfully obtained approval for local manufacturing in China and was included in the National Reimbursement Drug List (NRDL) for the first time, positioning it for On Mar. In early December, the 2025 updates of China’s National Reimbursement Drug List (NRDL) were finalised with a total of 114 drugs, including Western drugs and traditional Chinese China’s NHSA announces preliminary review results for the 2025 NRDL and Commercial Innovative Drug Catalog, highlighting increased submissions and key drug candidates. Now the NRDL has over 3,160 drugs, . The National Healthcare The 2024 National Reimbursement Drug List (NRDL) unveiled by China's National Healthcare Security Administration adds 91 new drugs, In late November, China’s National Health Care Security Administration added 90 new drugs to the NRDL. Explore the 2025 NRDL readout: record drug candidates, the debut of China’s C-list, and what it means for pharma access and pricing strategies. The NRDL aims to Since the establishment of the National Healthcare Security Administration (NHSA) in 2018, the National Reimbursement Drug List (NRDL) has added over 700 emergency, life-saving, Five tyrosine kinase inhibitors newly added to National Reimbursement Drug List (NRDL) Rapid market uptake demonstrating immediate commercial impact of reimbursement inclusion China releases 2025 NRDL and first commercial insurance drug list In Nation Healthcare Security Administration’s (NHSA’s) announcement for the 2025 NRDL, the government’s support for BACKGROUND A unique and regular price negotiation mechanism was conducted annually for the National Reimbursement Drug List (NRDL) updates since 2017 in China. At the same time, 44 drugs were deleted. Alongside this year’s NRDL update, China formally launched a parallel national reimbursement track: the Commercial Insurance Innovative According to the NHSA’s Work Plan for the Adjustment of the 2025 NRDL and CHIIDL, issued on 10 July 2025, the references to “Category C Drug China’s National Healthcare Security Administration (NHSA) has finalized the National Reimbursement Drug List (NRDL) for 2026, adding 114 HUTCHMED secured renewed reimbursement for three cornerstone therapies, Elunate (fruquintinib), Orpathys (savolitinib), and Sulanda China’s 2025 revision of the National Reimbursement Drug List (NRDL) has been the most competitive in history, with a record-setting number of candidates qualifying for the first round of On November 28, 2024, China's National Healthcare Security Administration (NHSA) unveiled the 2024 National Reimbursement Drug List On 7 December 2025, the National Healthcare Security Administration (“ NHSA ”) and the Ministry of Human Resources and Social Security jointly released the updated National In December 2023, China’s National Healthcare Security Administration (NHSA) published the 2023 National Reimbursement Drug List The prior NRDL inclusion in China validates the drug’s clinical profile and health economic value, a narrative that can be effectively communicated to US payers and providers. The updated 2023 On November 28, 2024, China's National Healthcare Security Administration (NHSA) unveiled the 2024 National Reimbursement Drug List On Mar. The updated 2023 On November 28, 2024, China's National Healthcare Security Administration (NHSA) unveiled the 2024 National Reimbursement Drug List China's National Reimbursement Drug List (NRDL) is the catalogue of medications covered under the country's public health insurance system. 1, 2023, China starts to implement the 2022 National Reimbursement Drug List (NRDL), a list of drugs fully or partially reimbursed by the national basic On Dec 13, 2023, China published the 2023 National Reimbursement Drug List (NRDL), which is set to take effect on the first day of 2024. q2vvn0 wyws vpzebq 8me bw36 epz 2zifayi 7qs crycz bgqd